mitomycin

Summary

Summary: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.

Top Publications

  1. ncbi Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway
    I Garcia-Higuera
    Department of Pediatric Oncology, Dana Farber Cancer Institute, and Department of Pediatrics, Children s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Mol Cell 7:249-62. 2001
  2. pmc Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin
    Leonard L Gunderson
    Mayo Clinic Arizona, Scottsdale, AZ 85259, USA
    J Clin Oncol 30:4344-51. 2012
  3. ncbi Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007
    Yoshihiko Segawa
    Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University Hospital, Kitaku, Okayama, Japan
    J Clin Oncol 28:3299-306. 2010
  4. pmc The structure-specific endonuclease Ercc1-Xpf is required to resolve DNA interstrand cross-link-induced double-strand breaks
    Laura J Niedernhofer
    Department of Cell Biology and Genetics, Erasmus Medical Center, Rotterdam, The Netherlands
    Mol Cell Biol 24:5776-87. 2004
  5. pmc Correction of chromosomal instability and sensitivity to diverse mutagens by a cloned cDNA of the XRCC3 DNA repair gene
    R S Tebbs
    Biology and Biotechnology Research Program, Lawrence Livermore National Laboratory, CA 94551 0808, USA
    Proc Natl Acad Sci U S A 92:6354-8. 1995
  6. ncbi BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance
    A Slupianek
    Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA 19122, USA
    Mol Cell 8:795-806. 2001
  7. ncbi Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study
    Niall C Tebbutt
    Austin Health, Studley Rd, Heidelberg, Victoria, 3084, Australia
    J Clin Oncol 28:3191-8. 2010
  8. ncbi Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial
    Roger D James
    The Kent Cancer Centre, Maidstone, UK
    Lancet Oncol 14:516-24. 2013
  9. ncbi Adhesion reduction after knee surgery in a rat model by mitomycin C
    Baris Kocaoglu
    Department of Orthopaedics and Traumatology, Acibadem University Faculty of Medicine, Barbaros Mah, Kentplus 1, Etap, C1 blok D 52, Yenisahra, Istanbul, Turkey
    Knee Surg Sports Traumatol Arthrosc 19:94-8. 2011
  10. ncbi Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer
    Timothy J Price
    The Queen Elizabeth Hospital, Woodville, SA 5011 Australia
    J Clin Oncol 29:2675-82. 2011

Detail Information

Publications343 found, 100 shown here

  1. ncbi Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway
    I Garcia-Higuera
    Department of Pediatric Oncology, Dana Farber Cancer Institute, and Department of Pediatrics, Children s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Mol Cell 7:249-62. 2001
    ..FA) is a human autosomal recessive cancer susceptibility disorder characterized by cellular sensitivity to mitomycin C and ionizing radiation...
  2. pmc Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin
    Leonard L Gunderson
    Mayo Clinic Arizona, Scottsdale, AZ 85259, USA
    J Clin Oncol 30:4344-51. 2012
    ..Intergroup Radiation Therapy Oncology Group (RTOG) 98-11 [A Phase III Randomized Study of 5-Fluorouracil (5-FU), Mitomycin, and Radiotherapy Versus 5-Fluorouracil, Cisplatin and Radiotherapy in Carcinoma of the Anal Canal], concurrent ..
  3. ncbi Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007
    Yoshihiko Segawa
    Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University Hospital, Kitaku, Okayama, Japan
    J Clin Oncol 28:3299-306. 2010
    ..To demonstrate the efficacy of docetaxel and cisplatin (DP) chemotherapy with concurrent thoracic radiotherapy (TRT) for patients with locally advanced non-small-cell lung cancer (LA-NSCLC)...
  4. pmc The structure-specific endonuclease Ercc1-Xpf is required to resolve DNA interstrand cross-link-induced double-strand breaks
    Laura J Niedernhofer
    Department of Cell Biology and Genetics, Erasmus Medical Center, Rotterdam, The Netherlands
    Mol Cell Biol 24:5776-87. 2004
    ..Treatment of wild-type cells with mitomycin C (MMC) induced gamma-H2AX foci and increased the amount of DSBs detected by pulsed-field gel electrophoresis...
  5. pmc Correction of chromosomal instability and sensitivity to diverse mutagens by a cloned cDNA of the XRCC3 DNA repair gene
    R S Tebbs
    Biology and Biotechnology Research Program, Lawrence Livermore National Laboratory, CA 94551 0808, USA
    Proc Natl Acad Sci U S A 92:6354-8. 1995
    ..implicated a human gene (defined as XRCC3; x-ray repair cross-complementing), which partially restored mitomycin C resistance to the mutant...
  6. ncbi BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance
    A Slupianek
    Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA 19122, USA
    Mol Cell 8:795-806. 2001
    ..Here we demonstrate that RAD51 is important for resistance to cisplatin and mitomycin C in cells expressing the BCR/ABL oncogenic tyrosine kinase...
  7. ncbi Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study
    Niall C Tebbutt
    Austin Health, Studley Rd, Heidelberg, Victoria, 3084, Australia
    J Clin Oncol 28:3191-8. 2010
    To determine whether adding bevacizumab, with or without mitomycin, to capecitabine monotherapy improves progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC) in an open-label, three-arm randomized trial.
  8. ncbi Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial
    Roger D James
    The Kent Cancer Centre, Maidstone, UK
    Lancet Oncol 14:516-24. 2013
    ..We investigated whether replacing mitomycin with cisplatin in chemoradiation improves response, and whether maintenance chemotherapy after chemoradiation ..
  9. ncbi Adhesion reduction after knee surgery in a rat model by mitomycin C
    Baris Kocaoglu
    Department of Orthopaedics and Traumatology, Acibadem University Faculty of Medicine, Barbaros Mah, Kentplus 1, Etap, C1 blok D 52, Yenisahra, Istanbul, Turkey
    Knee Surg Sports Traumatol Arthrosc 19:94-8. 2011
    The purpose of this study was to investigate the effect of Mitomycin C on reduction in intra-articular fibrotic adhesion formation after knee surgery. Twenty female Wistar Albino rats were divided into two equal study groups...
  10. ncbi Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer
    Timothy J Price
    The Queen Elizabeth Hospital, Woodville, SA 5011 Australia
    J Clin Oncol 29:2675-82. 2011
    ....
  11. ncbi The effect of mitomycin C in reducing intraarticular adhesion after knee surgery in rabbits
    Lianqi Yan
    Department of Orthopedics, Subei People s Hospital, Clinical Medical College of Yangzhou University, Nantong West Road 98, Yangzhou 225001, China
    Eur J Pharmacol 643:1-5. 2010
    b>Mitomycin C (MMC) is known to inhibit fibroblast proliferation through suppressing DNA dependent RNA synthesis...
  12. ncbi Acute scleral thinning after pterygium excision with intraoperative mitomycin C: a case report of scleral dellen after bare sclera technique and review of the literature
    Yi Yu Tsai
    Department of Ophthalmology, China Medical College Hospital, Taichung, Taiwan
    Cornea 21:227-9. 2002
    To describe a patient with scleral dellen after pterygium excision with intraoperative mitomycin C.
  13. ncbi Randomized trial of adjuvant chemotherapy with mitomycin, Fluorouracil, and Cytosine arabinoside followed by oral Fluorouracil in serosa-negative gastric cancer: Japan Clinical Oncology Group 9206-1
    Atsushi Nashimoto
    Department of Surgery, Niigata Cancer Center Hospital, 2 15 3 Kawagishicho, Niigata 951 8566, Japan
    J Clin Oncol 21:2282-7. 2003
    ....
  14. ncbi Changes induced by surgical and clinical factors in the pharmacology of intraperitoneal mitomycin C in 145 patients with peritoneal carcinomatosis
    Kurt Van Der Speeten
    Department of Surgical Oncology, Ziekenhuis Oost Limburg, Genk, Belgium
    Cancer Chemother Pharmacol 68:147-56. 2011
    ..b>Mitomycin C is a drug often used in this clinical setting...
  15. ncbi Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis from nonappendiceal colorectal carcinoma
    Perry Shen
    Wake Forest University Baptist Medical Center, Winston Salem, NC, USA
    Ann Surg Oncol 11:178-86. 2004
    ..We reviewed our experience using this approach for nonappendiceal colorectal cancer (NACC)...
  16. pmc Effect of prophylactic and therapeutic mitomycin C on corneal apoptosis, cellular proliferation, haze, and long-term keratocyte density in rabbits
    Marcelo V Netto
    The Cole Eye Institute, The Cleveland Clinic, Cleveland, Ohio 44195, USA
    J Refract Surg 22:562-74. 2006
    To determine the mechanism through which topical mitomycin C prevents and treats corneal haze after photorefractive keratectomy (PRK) and to examine the effects of dosage and duration of exposure.
  17. ncbi An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer
    Per Uno Malmstrom
    Uppsala University Hospital, Department of Urology, Uppsala, Sweden
    Eur Urol 56:247-56. 2009
    ..on meta-analyses of previously published results, guidelines recommend using either bacillus Calmette-Guérin (BCG) or mitomycin C (MMC) in these patients. Individual patient data (IPD) meta-analyses, however, are the gold standard.
  18. ncbi A prospective randomised trial of trabeculectomy using mitomycin C vs an ologen implant in open angle glaucoma
    A Rosentreter
    Department of Ophthalmology, University of Cologne, Koln, Germany
    Eye (Lond) 24:1449-57. 2010
    ..efficacy and complications of trabeculectomy with a biodegradable implant (ologen implant) vs trabeculectomy using mitomycin C (MMC) in patients with medically uncontrolled open-angle glaucoma in a prospective randomised clinical trial.
  19. ncbi Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project
    L Crino
    Department of Medical Oncology, Policlinico Hospital, Perugia, Italy
    J Clin Oncol 17:3522-30. 1999
    To compare gemcitabine and cisplatin (GC) with mitomycin, ifosfamide, and cisplatin (MIC) chemotherapy in patients with stage IIIB (limited to T4 for pleural effusion and N3 for supraclavicular lymph nodes) or stage IV non-small-cell ..
  20. pmc DNA damage is a prerequisite for p53-mediated proteasomal degradation of HIF-1alpha in hypoxic cells and downregulation of the hypoxia marker carbonic anhydrase IX
    Milota Kaluzova
    Department of Microbiology and Molecular Genetics, University of California at Irvine, College of Medicine, Irvine 92717, USA
    Mol Cell Biol 24:5757-66. 2004
    ..Activation of p53 by the DNA damaging agent mitomycin C (MC) was accompanied by a potent repression of CAIX expression and the CA9 promoter in MCF-7 but not in Saos-2 ..
  21. ncbi Imaging of blebs after phacotrabeculectomy with Ologen collagen matrix implants
    P Y Boey
    Singapore National Eye Centre, 11 Third Hospital Avenue, Singapore 168751, Singapore
    Br J Ophthalmol 95:340-4. 2011
    To analyse blebs of phacotrabeculectomies performed with Ologen collagen implants (ProTop & MediKing, Taipei, Taiwan) and to compare these with blebs of mitomycin C (MMC)–augmented phacotrabeculectomies.
  22. ncbi Bacillus subtilis RecG branch migration translocase is required for DNA repair and chromosomal segregation
    Humberto Sanchez
    Department of Microbial Biotechnology, Centro Nacional de Biotecnologia, CSIC, Madrid, E 28049 Spain
    Mol Microbiol 65:920-35. 2007
    ..After exposure to mitomycin C recG or ripX cells show a drastic defect in chromosome partitioning (approximately 40% of the cells), and this ..
  23. ncbi Ahmed valve implantation with adjunctive mitomycin C and 5-fluorouracil: long-term outcomes
    Jorge A Alvarado
    Department of Ophthalmology, Glaucoma Research Laboratory, University of California, San Francisco, San Francisco, California 94143, USA
    Am J Ophthalmol 146:276-284. 2008
    To evaluate long-term outcomes after Ahmed valve implantation in patients with glaucoma when using adjunctive intraoperative mitomycin C (MMC) and postoperative 5-fluorouracil (5-FU).
  24. ncbi Survival and induction of SOS in Escherichia coli treated with cisplatin, UV-irradiation, or mitomycin C are dependent on the function of the RecBC and RecFOR pathways of homologous recombination
    K L Keller
    Department of Biological Sciences, Bowling Green State University, Bowling Green, OH 43403, USA
    Mutat Res 486:21-9. 2001
    Resistance of tumors to drugs such as cisplatin and mitomycin C (MMC) is an important factor limiting their usefulness in cancer chemotherapy...
  25. ncbi Comparison of the effects of mitomycin C and 10-hydroxycamptothecin on an experimental intraarticular adhesion model in rabbits
    Xiaolei Li
    Department of Orthopedics, Clinical Medical College of Yangzhou University, Subei People s Hospital of Jiangsu Province, Yangzhou 225001, China
    Eur J Pharmacol 703:42-5. 2013
    The study was to compare the preventive effects of the local application of mitomycin C (MMC) and 10-hydroxycamptothecin (HCPT) on reducing intraarticular adhesion after knee surgery in rabbit model...
  26. pmc FAVL impairment of the Fanconi anemia pathway promotes the development of human bladder cancer
    Jayabal Panneerselvam
    University of Hawaii Cancer Center, University of Hawaii, Honolulu, HI, USA
    Cell Cycle 11:2947-55. 2012
    ..FAVL in bladder cancer cells as well as normal human cells confer an impaired FA pathway and hypersensitivity to Mitomycin C, similar to those found in FA cells, indicating that FAVL elevation may possess the same tumor promotion ..
  27. pmc Biodegradable collagen matrix implant vs mitomycin-C as an adjuvant in trabeculectomy: a 24-month, randomized clinical trial
    S Cillino
    Department of Experimental Biomedicine and Clinical Neuroscience, Ophthalmology Section, University of Palermo Italy, Palermo, Italy
    Eye (Lond) 25:1598-606. 2011
    To verify the safety and efficacy of Ologen (OLO) implant as adjuvant compared with low-dosage mitomycin-C (MMC) in trabeculectomy.
  28. ncbi Long-term outcomes of needle revision of trabeculectomy blebs with mitomycin C and 5-fluorouracil: a comparative safety and efficacy report
    Nitin Anand
    Department of Ophthalmology, Calderdale and Huddersfield NHS Trust, Huddersfield Royal Infirmary, Huddersfield
    J Glaucoma 18:513-20. 2009
    To report the long-term comparative outcomes for needle revision with 5-fluorouracil (5-FU) and mitomycin C (MMC) of failed trabeculectomy blebs.
  29. pmc Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87-04 and 98-11
    Edgar Ben-Josef
    Department of Radiation Oncology, University of Michigan, Ann Arbor, MI 48109, USA
    J Clin Oncol 28:5061-6. 2010
    ..To determine whether increased duration of radiation therapy (RT) and overall treatment (RX) time has a detrimental effect in anal cancer...
  30. ncbi Endoscopic dacryocystorhinostomy with adjunctive mitomycin C for canalicular obstruction
    Arie Y Nemet
    Department of Ophthalmology, Sydney Hospital and Sydney Eye Hospital, Macquarie Street, Sydney, Australia
    Orbit 26:97-100. 2007
    To report our experience in treating distal and common canalicular obstruction by trephination followed by topical low-dose mitomycin C (0.03%) and silicone intubation during endoscopic dacryocystorhinostomy (DCR).
  31. ncbi Involvement of the aldo-keto reductase, AKR1B10, in mitomycin-c resistance through reactive oxygen species-dependent mechanisms
    Toshiyuki Matsunaga
    Laboratory of Biochemistry, Gifu Pharmaceutical University, Gifu, Japan
    Anticancer Drugs 22:402-8. 2011
    ..colon cancer cells, we found that AKR1B10 was induced with acquisition of resistance to the anticancer drug mitomycin-c (MMC). In the resistant cells, treatment with an AKR1B10 inhibitor decreased their MMC tolerance...
  32. ncbi Intensity-modulated radiation therapy versus conventional radiation therapy for squamous cell carcinoma of the anal canal
    Jose G Bazan
    Department of Radiation Oncology, Stanford University, Stanford, CA, USA
    Cancer 117:3342-51. 2011
    ....
  33. ncbi Concentrations of mitomycin C in rabbit corneal tissue and aqueous humor after topical administration
    Jong Suk Song
    Department of Ophthalmology, Korea University College of Medicine, Seoul, Republic of Korea
    Cornea 25:S20-3. 2006
    To study the aqueous and corneal pharmacokinetics of mitomycin C (MMC) after single topical administration to the central cornea and to evaluate the effects of different concentrations and different application times on the aqueous ..
  34. pmc Regulation of the activation of the Fanconi anemia pathway by the p21 cyclin-dependent kinase inhibitor
    M A Rego
    Department of Cell and Molecular Biology, University of Rhode Island, Kingston, RI 02881, USA
    Oncogene 31:366-75. 2012
    ..Consequently, p21(-/-) cells exhibit increased levels of mitomycin C-inducible complex chromosomal aberrations and elevated γH2AX nuclear foci formation...
  35. ncbi Inhibition of homologous recombination in human cells by targeting RAD51 recombinase
    Fei Huang
    Department of Biochemistry and Molecular Biology, Drexel University College of Medicine, Philadelphia, Pennsylvania 19102, USA
    J Med Chem 55:3011-20. 2012
    ..We propose to use 1 for analysis of cellular functions of RAD51. Because DSB- and ICL-inducing agents are commonly used in anticancer therapy, specific inhibitors of RAD51 may also help to increase killing of cancer cells...
  36. ncbi Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy
    Lisa A Kachnic
    Department of Radiation Oncology, Boston Medical Center, Boston, MA 02118, USA
    Int J Radiat Oncol Biol Phys 82:153-8. 2012
    ..Chemoradiation for anal cancer yields effective tumor control, but is associated with significant acute toxicity. We report our multi-institutional experience using dose-painted IMRT (DP-IMRT)...
  37. ncbi The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial
    Rauf Taner Divrik
    Department of Urology, SB Tepecik Research and Teaching Hospital, Izmir, Turkey
    J Urol 175:1641-4. 2006
    We compared the outcomes of repeat transurethral resection plus intravesical mitomycin C with initial transurethral resection of bladder plus intravesical MMC in patients with newly diagnosed pT1 transitional cell carcinoma of the ..
  38. ncbi Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression
    A Bohle
    HELIOS Agnes Karll Hospital, Bad Schwartau, Germany
    Urology 63:682-6; discussion 686-7. 2004
    To compare the therapeutic efficacy of intravesical bacille Calmette-Guérin (BCG) with mitomycin C (MMC) on progression of Stage Ta and T1 bladder carcinoma.
  39. ncbi NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity
    R D Traver
    University of Southern California, School of Pharmacy, Los Angeles, California 90033
    Cancer Res 52:797-802. 1992
    ..is an obligate two-electron reductase which may play a role in the bioactivation of antitumor quinones such as mitomycin C (MMC)...
  40. ncbi Long-term comparison of primary trabeculectomy with 5-fluorouracil versus mitomycin C in West Africa
    Hanna Y Kim
    Department of Ophthalmology, Stanford University School of Medicine, Stanford, CA 97303, USA
    J Glaucoma 17:578-83. 2008
    To compare the long-term efficacy and safety of intraoperative 5-fluorouracil (5-FU) versus mitomycin-C (MMC) used adjunctively with primary trabeculectomy in a Black West African population.
  41. ncbi Incidence of late-onset bleb-related complications following trabeculectomy with mitomycin
    Peter W DeBry
    Department of Ophthalmology and Visual Sciences, University of Wisconsin, Madison, 2870 University Ave, Suite 206, Madison, WI 53705, USA
    Arch Ophthalmol 120:297-300. 2002
    To determine the incidence of late-onset bleb-related complications following trabeculectomy with mitomycin and to report the management and outcome of bleb leaks following trabeculectomy with mitomycin.
  42. pmc ATR-dependent phosphorylation of FANCA on serine 1449 after DNA damage is important for FA pathway function
    Natalie B Collins
    Department of Microbiology, University of Virginia School of Medicine, Charlottesville, USA
    Blood 113:2181-90. 2009
    ..Phosphorylation of FANCA on serine 1449 is a DNA damage-specific event that is downstream of ATR and is functionally important in the FA pathway...
  43. ncbi Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin
    I E Smith
    Royal Marsden National Health Service Trust, London and Surrey, UK
    J Clin Oncol 19:1336-43. 2001
    ..We have carried out a multicenter randomized trial comparing three versus six courses of chemotherapy...
  44. ncbi Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial
    Jaffer A Ajani
    Department of Gastrointestinal Medical Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Mail Stop 426, Houston, Texas 77030, USA
    JAMA 299:1914-21. 2008
    Chemoradiation as definitive therapy is the preferred primary therapy for patients with anal canal carcinoma; however, the 5-year disease-free survival rate from concurrent fluorouracil/mitomycin and radiation is only approximately 65%.
  45. ncbi Intraperitoneal chemohyperthermia and attempted cytoreductive surgery in patients with peritoneal carcinomatosis of colorectal origin
    O Glehen
    Department of Surgery, Centre Hospitalier Lyon Sud, Pierre Benite, France
    Br J Surg 91:747-54. 2004
    ..The purpose of this study was to evaluate the efficacy of intraperitoneal chemohyperthermia (IPCH) following cytoreductive surgery in patients with colorectal carcinomatosis...
  46. ncbi Impact of overall treatment time on local control of anal cancer treated with radiochemotherapy
    R Graf
    Center of Radiation Medicine, Campus Virchow Clinic, Charite Medical School, Humboldt University, Berlin, Germany
    Oncology 65:14-22. 2003
    ..consecutive days, during weeks 1 and 5) together with one (schedule A) or two (schedule B) short infusions of mitomycin C (10 mg/m(2)) during the first course of 5-FU...
  47. ncbi Prolonged antiscarring effects of ilomastat and MMC after experimental glaucoma filtration surgery
    Tina T L Wong
    Ocular Repair and Regeneration Biology Unit, Institute of Ophthalmology, London, UK
    Invest Ophthalmol Vis Sci 46:2018-22. 2005
    ..To determine the long-term antiscarring effect of ilomastat treatment after experimental glaucoma filtration surgery (GFS)...
  48. ncbi Positional cloning of a novel Fanconi anemia gene, FANCD2
    C Timmers
    Department of Molecular and Medical Genetics, Oregon Health Sciences University, Portland, OR 97201, USA
    Mol Cell 7:241-8. 2001
    ..thaliana, C. elegans, and Drosophila. Retroviral transduction of the cloned FANCD2 cDNA into FA-D2 cells resulted in functional complementation of MMC sensitivity...
  49. pmc BRCA2 is ubiquitinated in vivo and interacts with USP11, a deubiquitinating enzyme that exhibits prosurvival function in the cellular response to DNA damage
    Alan R Schoenfeld
    Derald H Ruttenberg Cancer Center, Mount Sinai School of Medicine, One Gustave L Levy Place, Box 1130, New York, NY 10029, USA
    Mol Cell Biol 24:7444-55. 2004
    ..Moreover, BRCA2 was constitutively ubiquitinated in vivo in the absence of detectable proteasomal degradation. Mitomycin C (MMC) led to decreased BRCA2 protein levels associated with increased ubiquitination, consistent with ..
  50. ncbi Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy
    D Elias
    Department of Oncological Surgery, Gustave Roussy Institute, Villejuif, France
    Cancer 92:71-6. 2001
    ..A new approach that combines maximal surgery with maximal regional chemotherapy has potential to cure selected patients who have colorectal PC. The authors have reported the oncologic results of this combined treatment...
  51. ncbi Reduced fertility and hypersensitivity to mitomycin C characterize Fancg/Xrcc9 null mice
    Mireille Koomen
    Department of Clinical Genetics and Human Genetics, VU University Medical Center, Van der Boechorststraat 7, 1081 BT Amsterdam, The Netherlands
    Hum Mol Genet 11:273-81. 2002
    ..and a hyper-responsiveness to the clastogenic and antiproliferative effects of the cross-linking agent mitomycin C (MMC)...
  52. ncbi Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205)
    Atsushi Ohtsu
    Division of Gastrointestinal Oncology Digestive Endoscopy, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
    J Clin Oncol 21:54-9. 2003
    To compare fluorouracil (FU) alone with FU plus cisplatin (FP) and with uracil and tegafur plus mitomycin (UFTM) for patients with advanced gastric cancer in a prospective, randomized, controlled trial.
  53. pmc Differential effects of mitomycin C and doxorubicin on P-glycoprotein expression
    R Maitra
    Department of Pharmacology and Toxicology, Dartmouth Medical School, Hanover, NH 03755-3835, USA
    Biochem J 355:617-24. 2001
    Previous studies have demonstrated that mitomycin C (MMC) and other DNA cross-linking agents can suppress MDR1 (multidrug resistance 1) gene expression and subsequent functional P-glycoprotein (Pgp) expression, whereas doxorubicin and ..
  54. ncbi Two-year survival of Ahmed valve implantation in the first 2 years of life with and without intraoperative mitomycin-C
    Faisal Al-Mobarak
    The King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia
    Ophthalmology 116:1862-5. 2009
    To evaluate the effect of intraoperative mitomycin-C (MMC) on polypropylene Ahmed glaucoma valve (AGV) survival 2 years after implantation during the first 2 years of life.
  55. pmc DNA adducts of decarbamoyl mitomycin C efficiently kill cells without wild-type p53 resulting from proteasome-mediated degradation of checkpoint protein 1
    Ernest K Boamah
    Department of Biological Sciences, Hunter College and the Graduate Center, City University of New York, 695 Park Avenue, New York, NY 10065, USA
    Chem Res Toxicol 23:1151-62. 2010
    The mitomycin derivative 10-decarbamoyl mitomycin C (DMC) more rapidly activates a p53-independent cell death pathway than mitomycin C (MC)...
  56. ncbi Endoscopic dacryocystorhinostomy not using canalicular silicone intubation tube with and without mitomycin C: a comparative study
    Mahmut Ozkiriş
    Department of Otolaryngology, Head and Neck Surgery, Tekden Medical Center, Kayseri, Turkey
    Eur J Ophthalmol 22:320-5. 2012
    To determine the outcome and safety of endoscopic dacryocystorhinostomy (EN-DCR) with the use of adjunctive mitomycin C (MMC) in nasolacrimal duct obstruction in adults.
  57. pmc Replication-independent repair of DNA interstrand crosslinks
    Hannah L Williams
    Institute for Cancer Genetics, Department of Genetics and Development, Columbia University, New York, NY 10032, USA
    Mol Cell 47:140-7. 2012
    ..Finally, we show that Pol κ participates in ICL repair in mammalian cells, particularly in G0. Our results identify key components of the RIR pathway and begin to unravel its mechanism...
  58. ncbi Effect of mitomycin C on endoscopic dacryocystorhinostomy
    Tayfun Apuhan
    Department of Otorhinolaryngology and Head and Neck Surgery, Izzet Baysal Medicine Faculty of Abant Izzet Baysal University, Bolu, Turkey
    J Craniofac Surg 22:2057-9. 2011
    The objectives of the study were to retrospectively analyze the efficacy of intraoperative mitomycin C (MMC) in endoscopic dacryocystorhinostomy (END-DCR) and compare it with external dacryocystorhinostomy (EXT-DCR).
  59. ncbi Clinical efficacy of modified preoperative neoadjuvant chemotherapy in the treatment of locally advanced (stage IB2 to IIB) cervical cancer: randomized study
    Huijun Chen
    Department of Gynecologic Oncology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei Province, China
    Gynecol Oncol 110:308-15. 2008
    ..However, these disadvantages may be overcome by a 'quick' high-dose scheme administered in a short period before surgery. Our purpose is to assess the efficacy of NAC with short cycle-length, high-dose agents for LACC...
  60. ncbi Comparison of local control effects of superselective transcatheter arterial chemoembolization using epirubicin plus mitomycin C and miriplatin for hepatocellular carcinoma
    Shiro Miyayama
    Department of Diagnostic Radiology, Fukuiken Saiseikai Hospital, 7 1 Funabashi, Wadanaka cho, Fukui 918 8503, Japan
    Jpn J Radiol 30:263-70. 2012
    To compare local control effects of superselective transcatheter arterial chemoembolization (TACE) using epirubicin (EPI) plus mitomycin C (M) and miriplatin (MPT) for hepatocellular carcinoma (HCC).
  61. ncbi Mitomycin C-enhanced revision endoscopic dacryocystorhinostomy: a prospective randomized controlled trial
    Sameh M Ragab
    Otolaryngology and Head and Neck Surgery, Tanta University Hospitals, Tanta, Egypt
    Otolaryngol Head Neck Surg 147:937-42. 2012
    1) To conduct an adequately powered randomized controlled trial investigating the safety and efficacy of mitomycin C-enhanced revision endoscopic dacryocystorhinostomy (DCR) and (2) to analyze causes of failure after primary endoscopic ..
  62. ncbi Outcome of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) chemotherapy and analysis of prognostic factors in patients with refractory advanced biliary tract cancer
    Kyu Hyoung Lim
    Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea
    Oncology 83:57-66. 2012
    The purpose of this study was to determine the efficacy and safety of infusional 5-fluorouracil (5-FU), doxorubicin, and mitomycin-C (iFAM) as salvage chemotherapy in biliary tract cancer (BTC) and to identify prognostic factors.
  63. pmc Genotypic and phenotypic diversity among induced, stx2-carrying bacteriophages from environmental Escherichia coli strains
    Cristina Garcia-Aljaro
    Departament de Microbiologia, Facultat de Biologia, Universitat de Barcelona, 08028 Barcelona, Spain
    Appl Environ Microbiol 75:329-36. 2009
    ..The lytic cycle of the bacteriophages was induced by mitomycin, and the bacteriophage fraction was isolated and used for morphological and genetic characterization...
  64. ncbi Insensitivity of the in vitro cytokinesis-block micronucleus assay with human lymphocytes for the detection of DNA damage present at the start of the cell culture
    Günter Speit
    Universitat Ulm, Institut fur Humangenetik, D 89069 Ulm, Germany
    Mutagenesis 27:743-7. 2012
    ..ethyl nitrosourea; ENU), styrene oxide (SO), (±)-anti-B[a]P-7,8-dihydrodiol-9,10-epoxide (BPDE) and mitomycin C (MMC)...
  65. pmc RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal
    Lisa A Kachnic
    Department of Radiation Oncology, Boston University Medical Center, Boston, Massachusetts 02118, USA
    Int J Radiat Oncol Biol Phys 86:27-33. 2013
    ..grade 2+ combined acute gastrointestinal and genitourinary adverse events (AEs) of 5-fluorouracil (5FU) and mitomycin-C (MMC) chemoradiation for anal cancer by at least 15% compared with the conventional radiation/5FU/MMC arm from ..
  66. ncbi Adjuvant chemotherapy with 5-fluorouracil, doxorubicin and mitomycin-C (FAM) for 6 months after curative resection of gastric carcinoma
    D H Koo
    Division of Oncology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, 388 1 Pungnap 2dong, Songpa Gu, Seoul 138 736, Republic of Korea
    Eur J Surg Oncol 33:843-8. 2007
    This study aimed to evaluate the efficacy and safety of 5-fluorouracil (5-FU), doxorubicin and mitomycin-C (FAM) adjuvant chemotherapy in patients who had undergone curative resection of gastric carcinoma.
  67. ncbi Cytoreductive surgery and peri-operative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome
    P H Sugarbaker
    Washington Cancer Institute, Washington, DC, USA
    Eur J Surg Oncol 27:239-43. 2001
    ..The intraperitoneal chemotherapy was given in the peri-operative period, starting with mitomycin C...
  68. ncbi Mitomycin C resistance induced by TCF-3 overexpression in gastric cancer cell line MKN28 is associated with DT-diaphorase down-regulation
    N Sagara
    Genetics and Cell Biology Section, Genetics Division, National Cancer Center Research Institute, Tokyo, Japan
    Cancer Res 60:5959-62. 2000
    ..Three independent MKN28 transformants overexpressing TCF-3 showed about 8-fold resistance to mitomycin C (MMC; IC50, 2.4 microg/ml) compared with MKN28 vector transfectants (IC50 = 0.3 microg/ml)...
  69. ncbi Trabeculectomy with mitomycin-C in the treatment of pediatric glaucomas
    P A Sidoti
    Department of Ophthalmology, The New York Eye and Ear Infirmary, New York 10003, USA
    Ophthalmology 107:422-9. 2000
    To evaluate the effectiveness and safety of trabeculectomy with mitomycin-C (MMC) in the management of childhood glaucomas.
  70. ncbi Long-term survival of peritoneal carcinomatosis of colorectal origin
    Vic J Verwaal
    Department of Surgery, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands
    Ann Surg Oncol 12:65-71. 2005
    ..In The Netherlands Cancer Institute, this treatment has been performed since 1995. The long tradition of this treatment enabled us to study long-term survival in detail...
  71. ncbi Long-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-C alone as adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC)
    Renzo Colombo
    Department of Urology, University Vita Salute San Raffaele, Milan, Italy
    BJU Int 107:912-8. 2011
    To present long-term efficacy data of intravesical thermochemotherapy vs chemotherapy alone with mitomycin-C (MMC) randomly administered to patients with non-muscle-invasive bladder cancer (NMIBC) as an adjuvant treatment after ..
  72. ncbi Effects of intraperitoneal chemotherapy with mitomycin C on the prevention of peritoneal recurrence in colorectal cancer patients with positive peritoneal lavage cytology findings
    Shingo Noura
    Department of Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan
    Ann Surg Oncol 18:396-404. 2011
    ..The aim of this study was to investigate the effects of intraperitoneal chemotherapy (IPC) with mitomycin C (MMC) on preventing peritoneal recurrence in CRC patients with positive peritoneal lavage cytology findings.
  73. ncbi Closed abdomen hyperthermic intraperitoneal chemotherapy with irinotecan and mitomycin C: a phase I study
    Eddy Cotte
    Department of Digestive Surgery, Centre Hospitalo Universitaire Lyon Sud, Hospices Civils de Lyon, Pierre Benite Cedex, France
    Ann Surg Oncol 18:2599-603. 2011
    ..The objective of this phase I study is to determine the maximum tolerated dose of irinotecan (CPT-11) when used with mitomycin C (MMC) for closed abdomen HIPEC.
  74. ncbi Safety and efficacy of using off-label bevacizumab versus mitomycin C to prevent bleb failure in a single-site phacotrabeculectomy by a randomized controlled clinical trial
    Sabyasachi Sengupta
    Glaucoma Services, Aravind Eye Hospital, Pondicherry, India
    J Glaucoma 21:450-9. 2012
    To analyze the safety and efficacy of bevacizumab (1.25 mg/0.05 mL) versus 0.03% mitomycin C (MMC) for preventing bleb failure in patients undergoing single-site phacotrabeculectomy for primary open-angle glaucoma or chronic angle-..
  75. ncbi Toxicity against gastric cancer cells by combined treatment with 5-fluorouracil and mitomycin c: implication in oxidative stress
    Toshiyuki Matsunaga
    Laboratory of Biochemistry, Gifu Pharmaceutical University, Gifu, 502 8585, Japan
    Cancer Chemother Pharmacol 66:517-26. 2010
    Combined chemotherapy of 5-fluorouracil (5FU) and mitomycin c (MMC) is clinically used for gastric cancer, but the precise conditions and molecular mechanism of these agents when used together remain unclear...
  76. ncbi A phase III randomized trial of 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil and mitomycin C versus 5-fluorouracil alone in curatively resected gastric cancer
    H M Chang
    Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
    Ann Oncol 13:1779-85. 2002
    A phase III single-center randomized trial was performed in order to determine whether the addition of mitomycin C (MMC) and/or doxorubicin to 5-fluorouracil (5-FU) as adjuvant chemotherapy could influence survival in patients with ..
  77. ncbi In vitro analyses of the anti-fibrotic effect of SPARC silencing in human Tenon's fibroblasts: comparisons with mitomycin C
    Li Fong Seet
    Ocular Wound Healing and Therapeutics, Singapore Eye Research Institute, Singapore
    J Cell Mol Med 16:1245-59. 2012
    ..b>Mitomycin C-treated HTFs were used for comparison...
  78. ncbi Enhanced sensitivity of Escherichia coli uvrB mutants to mitomycin C points to a UV-C distinct repair for DNA adducts
    Leonardo S Vidal
    Lab Radiobiologia Molecular, Inst Biofisica Carlos Chagas Filho, CCS UFRJ, 21949540, Rio de Janeiro, RJ, Brazil
    Chem Res Toxicol 19:1351-6. 2006
    ..For this reason, cross-linking agents such as mitomycin C (MC) have been used in cancer chemotherapy...
  79. ncbi Intraoperative mitomycin C versus intraoperative 5-fluorouracil for trabeculectomy: a systematic review and meta-analysis
    Zhong Jie Lin
    Department of Ophthalmology, Shanghai Changzheng Hospital, Second Military Medical University, Shanghai, China
    J Ocul Pharmacol Ther 28:166-73. 2012
    The aim of this study was to assess the intraoperative application of mitomycin C (MMC) compared to 5-fluorouracil (5-FU) on the outcome of trabeculectomy and to examine the balance of risk and benefit.
  80. ncbi Trabeculectomy with mitomycin C in pseudophakic patients with open-angle glaucoma: outcomes and risk factors for failure
    Hector Fontana
    Glaucoma Division, Jules Stein Eye Institute, University of California, Los Angeles, California, USA
    Am J Ophthalmol 141:652-9. 2006
    To evaluate tonometric outcomes of trabeculectomy with mitomycin C in pseudophakic patients with open-angle glaucoma and associated risk factors for failure.
  81. pmc Serious corneoscleral complications after pterygium excision with mitomycin C
    B Safianik
    Br J Ophthalmol 86:357-8. 2002
  82. pmc Comparison of Shiga toxin production by hemolytic-uremic syndrome-associated and bovine-associated Shiga toxin-producing Escherichia coli isolates
    Jenny M Ritchie
    Division of Geographic Medicine and Infectious Diseases, Tufts New England Medical Center, Boston, Massachusetts 02111, USA
    Appl Environ Microbiol 69:1059-66. 2003
    ..bacteriophage encoded, and their production has been shown to be enhanced by prophage-inducing agents such as mitomycin C in a limited number of clinical STEC isolates...
  83. ncbi Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non small cell lung cancer. A multicenter, randomized phase III trial
    Adriano Paccagnella
    Department of Medical Oncology, SS Giovanni and Paolo Hospital, Campo S Giovanni e Paolo, 30100 Venice, Italy
    Lung Cancer 43:83-91. 2004
    ..The combination of cisplatin with Mitomycin and Vinblastine was one of the most frequently used in the palliative setting at the time of design of our study.
  84. ncbi Effect of intraurethral Mitomycin-C on healing and fibrosis in rats with experimentally induced urethral stricture
    Ali Ayyildiz
    Ankara Training and Education Hospital, 2nd Urology Clinic, Turkey
    Int J Urol 11:1122-6. 2004
    ..After the recognition that topical application of Mitomycin-C (MMC) inhibits fibroblast proliferation and is effective in preventing scar formation, many studies have been ..
  85. ncbi A phase II study of biweekly mitomycin C and irinotecan combination therapy in patients with fluoropyrimidine-resistant advanced gastric cancer: a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group (JCOG0109-DI Trial)
    Tetsuya Hamaguchi
    Division of Gastrointestinal Oncology, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo, 104 0045, Japan
    Gastric Cancer 14:226-33. 2011
    Preclinical studies have shown that mitomycin C (MMC) acts synergistically with irinotecan (CPT-11)...
  86. pmc Phosphorylation of FANCD2 on two novel sites is required for mitomycin C resistance
    Gary P H Ho
    Dana Farber Cancer Institute, Department of Radiation Oncology, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Mol Cell Biol 26:7005-15. 2006
    ..These findings further support the functional connection of ATM/ATR kinases and FANCD2 in the DNA damage response and support a role for the FA pathway in the coordination of the S phase of the cell cycle...
  87. ncbi Scleral melting 16 years after pterygium excision with topical Mitomycin C adjuvant therapy
    W M Wan Norliza
    Department of Ophthalmology, School of Medical Sciences, Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan, Malaysia
    Cont Lens Anterior Eye 29:165-7. 2006
    To report a case of scleral melting noted 16 years after pterygium excision with postoperative adjuvant topical Mitomycin C (MMC).
  88. pmc Persistent DNA damage caused by low levels of mitomycin C induces irreversible cell senescence
    Elise McKenna
    Brander Cancer Research Institute, Department of Pathology, New York Medical College, Valhalla, NY, USA
    Cell Cycle 11:3132-40. 2012
    ..human non-small cell lung carcinoma A549 cells can undergo senescence when treated with the DNA alkylating agent mitomycin C (MMC). While exposure of A549 cells to 0.1 or 0...
  89. ncbi Low-dose intraoperative mitomycin C as chemoadjuvant for pterygium surgery
    H C Cheng
    Department of Ophthalmology, College of Medicine, National Cheng Kung University, Tainan, Taiwan, ROC
    Cornea 20:24-9. 2001
    PURPOSE: To evaluate the efficacy and safety of low-dose intraoperative mitomycin C (MMC) during bare sclera procedure and to compare the rates of pterygium recurrence between recurrent pterygium patients treated with adjuvant MMC and ..
  90. ncbi 2004 Dr. Gary J. Becker Young Investigator Award: Relative thermosensitivity of cytotoxic drugs used in transcatheter arterial chemoembolization
    Kamran Ahrar
    Department of Interventional Radiology, The University of Texas M D Anderson Cancer Center, Unit 325, 1515 Holcombe Boulevard, Houston, TX 77030 4009, USA
    J Vasc Interv Radiol 15:901-5. 2004
    ..Therefore, in the present study, the relative thermosensitivity of cytotoxic drugs commonly used in TACE was studied...
  91. ncbi Sequencing, targeted mutagenesis and expression of a recA gene required for the extreme radioresistance of Deinococcus radiodurans
    P D Gutman
    Department of Pathology, F E Hebert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD 20814 4799
    Gene 141:31-7. 1994
    ..coli is lethal, suggesting that the mode of interaction of the deinococcal RecA protein with nucleic acids or other cellular proteins differs at least in part from RecA of E. coli...
  92. ncbi Outcomes in 15 patients with conjunctival melanoma treated with adjuvant topical mitomycin C: complications and recurrences
    Lauren C Ditta
    Hamilton Eye Institute, Department of Ophthalmology, University of Tennessee Health Science Center, Memphis, Tennessee, USA
    Ophthalmology 118:1754-9. 2011
    To report the long-term complications and rate of local recurrence in a cohort of patients with histopathologically confirmed conjunctival melanoma (CM) treated with adjuvant topical mitomycin C (MMC).
  93. ncbi Nonlaser endoscopic endonasal dacryocystorhinostomy with adjunctive mitomycin C in nasolacrimal duct obstruction in adults
    Angela M Dolmetsch
    Division of Orbital, Ophthalmic Plastic and Reconstructive Surgery, Clinica de Oftalmología de Cali, Universidad del Valle, Cali, Colombia
    Ophthalmology 117:1037-40. 2010
    To determine the outcome and safety of nonlaser endonasal dacryocystorhinostomy (NLEN-DCR) with the use of adjunctive mitomycin C (MMC) in congenital, traumatic, and primary acquired nasolacrimal duct obstruction in adults.
  94. ncbi Postoperative 5-fluorouracil versus intraoperative mitomycin C in high-risk glaucoma filtering surgery: extended follow up
    Cengiz Akarsu
    Department of Ophthalmology, School of Medicine, University of Kirikkale, Kirikkale, Turkey
    Clin Experiment Ophthalmol 31:199-205. 2003
    To compare the long-term efficacy and safety of postoperative subconjunctival 5-fluorouracil (5-FU) injections with that of intraoperative mitomycin C (MMC) in eyes at high risk for failure of trabeculectomy.
  95. ncbi Comparison of posterior capsule opacification in rabbits receiving either mitomycin-C or distilled water for sealed-capsule irrigation during cataract surgery
    Su Young Kim
    Department of Ophthalmology and Visual Science, College of Medicine, The Catholic University of Korea, Seoul, Korea
    Clin Experiment Ophthalmol 35:755-8. 2007
    To compare posterior capsule opacification (PCO) in rabbits who undergo cataract surgery and receive either mitomycin-C (MMC) or distilled water (DW) during sealed-capsule irrigation (SCI)...
  96. ncbi Phase I-II study of irinotecan combined with mitomycin-C in patients with advanced gastric cancer
    T Yamao
    Department of Internal Medicine, Cancer Institute Hospital, Tokyo, National Cancer Center Hospital, Tokyo, Japan
    Ann Oncol 12:1729-35. 2001
    Irinotecan (CPT-11) shows synergism with mitomycin-C (MMC) in a preclinical setting...
  97. ncbi Mitomycin--C-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: cumulative toxicity of an old drug in a new era
    Roland El-Ghazal
    Hospital of St Raphael, New Haven, CT, USA
    Clin Colorectal Cancer 10:142-5. 2011
    b>Mitomycin-C (MMC) is a first-line therapy for anal squamous cell carcinoma (ASCC), and it continues to be used for several other indications...
  98. ncbi Punctal-canalicular stenosis associated with mitomycin-C for corneal epithelial dysplasia
    Kathryn Billing
    Department of Ophthalmology, Royal Adelaide Hospital, The University of Adelaide, Adelaide, Australia
    Am J Ophthalmol 136:746-7. 2003
    To report a case of punctal-canalicular stenosis after topical mitomycin C use for corneal dysplasia. To the authors' knowledge, this association has not previously been described.
  99. ncbi Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer
    Suee Lee
    Department of Internal Medicine, Dong A University College of Medicine, Busan 602 715, Korea
    Am J Clin Oncol 32:348-52. 2009
    ..We attempted to evaluate the efficacy and safety of a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) as a second-line treatment in pancreatic and biliary tract cancer.
  100. ncbi Urinary pH is highly associated with tumor recurrence during intravesical mitomycin C therapy for nonmuscle invasive bladder tumor
    Takahiro Maeda
    Department of Urology, Keio University School of Medicine, Tokyo, Japan
    J Urol 185:802-6. 2011
    In recent years some reports have suggested without any significant evidence that mitomycin C instillation would be more effective with urinary alkalinization...
  101. pmc Corneal molecular and cellular biology update for the refractive surgeon
    Marcella Q Salomao
    The Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
    J Refract Surg 25:459-66. 2009
    ..To review clinically relevant progress in understanding cellular and molecular interactions in the cornea that relate to refractive surgical outcomes in patients...

Research Grants62

  1. Suppression of Ocular Scarring - Controlled Delivery of an ALK-5 Inhibitor
    Hiroshi Nakamura; Fiscal Year: 2013
    ..As subconjunctival anti-scarring treatments, antimetabolites, generally 5-fluorouracil (5-FU) and mitomycin-C (MMC), are commonly used to reduce post-operative scarring at the site of GFS and enhance the long-term ..
  2. Role of Beta Spectrin and Smad in Alcohol Induced Liver and GI Cell Proliferation
    Lopa Mishra; Fiscal Year: 2013
    ..TGF-[unreadable]/[unreadable]2SP accumulate DNA damage that is exacerbated by DNA cross-linking agents such as mitomycin C similar to P57 null cells and Fanconi anemia cell lines...
  3. REGULATION OF STROMAL WOUND HEALING BY GROWTH FACTORS
    GREGORY SCOTT SCHULTZ; Fiscal Year: 2012
    ..Clinical trials of anti-inflammatory steroids have not shown statistically significant benefit, and mitomycin C treatment carries the risk serious side effects...
  4. DNA recombinational repair in Helicobacter pylori
    Ge Wang; Fiscal Year: 2010
    ..pylori by screening for mitomycin C-sensitive strains from a random transposon mutagenesis library...
  5. Searching for a New Fanconi Anemia-BRCA Pathway Gene on Chromosome 11p
    NIALL GEORGE HOWLETT; Fiscal Year: 2010
    ..FA patient cells are hypersensitive to DNA crosslinking agents, e.g. mitomycin C (MMC)...
  6. Synthesis, Biosynthesis, and Structure of Antitumor Agents
    Thomas R Hoye; Fiscal Year: 2013
    ..from daunomycin), etoposide/teniposide (from podophyllotoxin), irinotecan/topotecan (from camptothecin), mitomycin, mylotarg (from calicheamicin), streptozotocin, taxol (and docetaxel), vincristine, and vinblastine...
  7. Novel Mechanisms by which RAD18 and POLZ affect Response to Anticancer Agents
    CHRISTINE ELIZABETH CANMAN; Fiscal Year: 2012
    ..colocalizes with DNA double strand breaks (DSBs) when cells are exposed to ionizing radiation, camptothecin, Mitomycin C, or cisplatin and that depletion of Rev3 leads to cellular phenotypes consistent with cells deficient in DSB ..
  8. Rapid release paclitaxel nanoparticles for bladder cancer intravestical therapy
    Ze Lu; Fiscal Year: 2009
    ..a series of preclinical and clinical studies, an important lesson learned is that the efficacy of intravesical mitomycin (MMC) or doxorubicin therapy is limited by two factors, i.e...
  9. The role of PPAR{gamma} ligands in corneal wound healing and optics
    Krystel R Huxlin; Fiscal Year: 2013
    ..efficient inhibitors of fibrosis in PRK-induced corneal wound healing than anti-TGF2 antibodies, steroids or Mitomycin C...
  10. Intra-bladder MMC &suramin for nonmuscle-invading &locally advanced bladder ca
    Ze Lu; Fiscal Year: 2012
    ..The most commonly used chemotherapeutic agents for intravescial therapy are mitomycin C (MMC) and doxorubicin...
  11. Targeting Somatic Homologous Recombination in Solid Tumors
    MIGUEL ANGEL VILLALONA; Fiscal Year: 2013
    ..establish the safety and practicality of treating patients with FA deficient tumors with the combination of mitomycin C and ABT-888;and 4- generate and in vitro and in vivo system capable of evaluating and optimizing combinations ..
  12. Predicting pancreatic cancer responses for a Parp inhibitor-based clinical trial
    Michael G Goggins; Fiscal Year: 2010
    ..to a low-dose DNA strand break regimen of monthly cycles of chemotherapy (irinotecan, cisplatin, bleomycin and mitomycin C) with or without the oral Parp inhibitor, olarparib...
  13. FANCD2 Monoubiquitination in DNA Damage Responses
    Paul R Andreassen; Fiscal Year: 2012
    ..Monoubiquitination of FANCD2 is required for resistance to the crosslinker mitomycin C...
  14. Combination chemo-siRNA gene therapy of nonmuscle-invading bladder cancer
    Ze Lu; Fiscal Year: 2012
    ..The most commonly used chemotherapeutic agents for intravescial therapy are mitomycin C (MMC) and doxorubicin...
  15. Regulation of the Fanconi Anemia Pathway by Ubiquitination
    ALAN D D'ANDREA; Fiscal Year: 2013
    ..characterized by progressive bone marrow failure, leukemia susceptibility, and cellular hypersensitivity to Mitomycin C and other DNA crosslinkers...
  16. Novel Molecular and Cellular Therapies in Fanconi Anemia
    David Williams; Fiscal Year: 2009
    ..This feature increases the sensitivity of FA cells to DNA bifunctional cross-linking agents such as mitomycin C (MMC) and diepoxybutane (DEB)...
  17. LEUKOCYTE, ENZYME AND DRUG CHEMILUMINESCENCE STUDIES
    JEFFREY KANOFSKY; Fiscal Year: 1990
    ..be studied include bleomycin, doxorubicin, daunorubicin, carminic acid, mithramycin, chromomycin A3, olivomycin, mitomycin C, VP-16 streptonigrin, procarbazine, paraquat, cis-platinum and gossypol...
  18. HYPOTHALAMIC HORMONES IN PANCREATIC CANCER
    Andrew Schally; Fiscal Year: 1991
    ..g. Ifosfamide, Mitomycin C and Cisplatin; e) microcapsules of N-Ac-D- p-C1-Phe-1,2, D-Trp-3,D-Arg-6,D-Ala-10-LH-RH (Antagonist I), or ..
  19. Sustained Drug Release for Antifibrosis
    Weiliam Chen; Fiscal Year: 2009
    ..13-34 5-fluorouracil and mitomycin are the most commonly utilized agents, however, the former is limited by its short duration of action, which ..
  20. MicroRNAs Regulating The Fanconi Anemia-BRCA Pathway
    Toshiyasu Taniguchi; Fiscal Year: 2009
    DESCRIPTION (provided by applicant): DNA-crosslinking agents such as cisplatin, carboplatin, cyclophosphamide, mitomycin C and melphalan are widely-used drugs for treatment of cancers including leukemia, lymphoma, and myeloma...
  21. PHARMACODYNAMIC CORRELATES IN ADVANCED GASTRIC CANCER
    Charles Coltman; Fiscal Year: 1992
    ..a superior response rate and associated median survival than FAM chemotherapy (5-Fluorouracil, doxorubicin, and mitomycin- C)...
  22. DESIGN OF ANTITUMOR REDUCTIVE ALKYLATORS
    EDWARD SKIBO; Fiscal Year: 1992
    ..g. mitomycin C, the saframycins, and the anthracyclines)...
  23. PATHOGENESIS OF CORNEAL EDEMA AFTER INTRAOCULAR SURGERY
    Henry Edelhauser; Fiscal Year: 2006
    ..will evaluate endothelial cells that are transit amphifying cells, terminally differential cells, the effect of mitomycin C, glaucoma drainage implants and polymegathism on the endothelial cell population in the three zones of ..
  24. Airborne Nanoparticles for Therapeutic Applications
    Amir Naqwi; Fiscal Year: 2009
    ..Besides the safety and efficacy study with 5-FU, efficacy of a highly potent drug, Mitomycin C (with or without heparin), will also be examined using the above PVR models...
  25. PHARMACODYNAMICS OF AGENTS FOR BLADDER CANCER THERAPY
    JESSIE AU; Fiscal Year: 2003
    ..Results of our studies on mitomycin C (MMC) indicate several treatment conditions which need optimization and a low sensitivity of high stage, high ..
  26. FAA AND FAD GENES AND PROTEINS
    Manuel Buchwald; Fiscal Year: 1999
    ..FA cells are hypersensitive to certain cytotoxic and clastogenic agents, for example, mitomycin C (MMC) and diepoxybutane (DEB) and FA cells exhibit chromosome aberrations...
  27. LH-RH ANALOGS IN BREAST AND OVARIAN CANCER
    Andrew Schally; Fiscal Year: 1991
    ..microcapsules thereof; b) with antiestrogens such as Tamoxifen; c) chemotherapeutic agents such as Ifosfamide, Mitomycin C and Cisplatinum; 3) controlled delivery systems based on the microcapsule (pLGA) or implant formulations of ..
  28. IMPLANTED ELECTRODE-ARRAYS QUANTIFY NERVE REGENERATION
    Christian Krarup; Fiscal Year: 1990
    ..To inhibit Schwann cells, neurotoxic inhibitors (Mitomycin C or Doxorubicin) will be injected into the distal denervated nerve stump...
  29. USE OF LH-RH AGONISTS & ANTAGONISTS IN PROSTATE CANCER
    Andrew Schally; Fiscal Year: 1993
    ..of various agonists and antagonists of LH-RH containing cytotoxic radicals such as Melphalan, Aziridine and Mitomycin C, the evaluation of their binding to LH-RH receptors and testing of their effects in animal models of prostate ..
  30. BIOCHEMISTRY AND MOLECULAR GENETICS OF MITOMYCIN BIOSYNT
    David Sherman; Fiscal Year: 2003
    ..the molecular mechanisms controlling the biosynthesis of and cellular resistance to the antitumor antibiotic, mitomycin C...
  31. DNA CROSSLINK REPAIR ENZYMES IN HUMAN CELLS
    THOMAS BRENT; Fiscal Year: 1992
    ..g., clomesome, mitozolomide, procarbazine, mitomycin C and cisplatin): We shall determine GATase activity in a variety of human tumor lines, in- cluding tumors of ..
  32. SYNERGY OF TUMOR CHEMOTHERAPY AND HOST IMMUMITY
    SHELDON DRAY; Fiscal Year: 1991
    ..by the ability of the spleen cells to become cytotoxic for the tumor cells upon in vitro immunization with mitomycin C-treated tumor cells...
  33. MITOMYCINS UNRAVELLED
    Harold Kohn; Fiscal Year: 1999
    DESCRIPTION: Mitomycin C is a clinically significant antineoplastic antibiotic used widely in combination chemotherapy for the treatment of patients with advanced breast cancer and cervical ovarian cancers...
  34. FANCONI ANEMIA--PATHOPHYSIOLOGY AND TREATMENT
    Christopher Walsh; Fiscal Year: 1999
    ..The hallmark of the FA disease is the hypersensitivity of FA cells to DNA cross linking agents such as mitomycin C...
  35. Bladder Tumor Targeting by Intravesical Paclitaxel
    Ze Lu; Fiscal Year: 2005
    ..b>Mitomycin C (MMC) and doxorubicin are among the most commonly used drugs...
  36. Conference Grant: "DNA Alkylation: From Natural Products to Chemotherapy"
    Kent Gates; Fiscal Year: 2006
    ..novel natural products with very potent activity will be discussed including duocarmycin, azinomycin, mitomycin C, the illudins, and leinamycin...
  37. Adducts of mitomycin C with nucleotides.
    Maria Tomasz; Fiscal Year: 2006
    DESCRIPTION (provided by applicant): Mitomycin C (MC) is a natural antitumor antibiotic used in the clinic for cancer chemotherapy. MC generates six different DNA adducts in tumor cells...
  38. Biomaterials for Adhesion-Free Tendon Repair
    Glenn Prestwich; Fiscal Year: 2005
    ..we recently developed a novel in situ crosslinkable HA hydrogel that can contain the antiproliferative drug mitomycin C (MMC) via a covalent linkage...
  39. AATYK--A NOVEL APOPTOSIS ASSOCIATED TYROSINE KINASE
    E Reddy; Fiscal Year: 2002
    ..apoptotic stimuli produced by different xenobiotic agents such as calphostin C, methotrexate etoposide, and mitomycin C result in the induction of AATYK, [b] to test whether ectopic over-expression of AATYK renders v-abl and bcr-..
  40. BRCA1 and Familial Pancreatic Cancer
    Alison Klein; Fiscal Year: 2007
    ..Fanconi defective cell lines are hypersensitive to the DNA crosslinking agent mitomycin C and to a lesser extent cis-platin...
  41. PHARMACODYNAMICS OF AGENTS FOR BLADDER CANCER
    JESSIE AU; Fiscal Year: 1991
    ..is to examine the pharmacokinetics and pharmacodynamics (drug concentration-time-effect relationship) of mitomycin C, thiotepa and doxorubicin which are used in the intravesical treatment of urinary bladder cancers...
  42. MECHANISMS OF DRUG ACTION IN TUMOR CELL DIFFERENTIATION
    MICHAEL MORIN; Fiscal Year: 1990
    ..chemotherapeutic agents which inhibit topoisomerase, such as m-AMSA or Adriamycin, and other drugs such as mitomycin C or cytosine arabinoside which are not effective inhibitors of this enzyme, will be evaluated on the basis of ..
  43. Transposon-mediated Gene Therapy for Fanconi Anemia
    PERRY HACKETT; Fiscal Year: 2004
    ..type C or A, respectively, testing these cell populations for reduced sensitivity to the DNA damaging agent mitomycin C as well as for transposition by molecular genetic analysis...
  44. INSECT SPECIES FOR ASSESSMENT OF PROXIDANT TOXICITY
    SAMI AHMAD; Fiscal Year: 1992
    ..the potential of using a model insect species for assessing oxidative stress exerted by an anticancer drug mitomycin C, and an antifungal compound, dichlone...
  45. FAC IN STEM CELL FUNCTION AND OXYGEN SENSITIVITY
    Laura Haneline; Fiscal Year: 2003
    ..failure, increased incidence of malignancies, and hypersensitivity to bifunctional alkylating agents such as mitomycin C (MMC)...
  46. MOLECULAR PATHOPHYSIOLOGY OF FANCONI ANEMIA
    Gary Kupfer; Fiscal Year: 1999
    ..Cells from patients with FA are hypersensitive to DNA cross- linking agents, notably mitomycin C (MMC) and diepoxybutane (DEB), and the molecular defect is presumably one of DNA repair...
  47. Symposium: Progress in Fanconi Anemia Research
    Grover Bagby; Fiscal Year: 2001
    ..Cells from FA patients exhibit hypersensitivity to alkylating agents such as mitomycin C (MMC) and diepoxybutane (DEB) and this hypersensitivity is currently used as the basis for the diagnostic ..
  48. Defining the role of FANCD2 in homology-directed DNA Repair
    Steven Margossian; Fiscal Year: 2009
    ..FA cells are exquisitely sensitive to interstrand cross-linkers, such as Mitomycin C (MMC), but relatively resistant to ionizing radiation (IR), although both mutagens generate double-strand ..
  49. PHENOTYPE SCREENS FOR BONE MARROW FAILURE
    Michael Barry; Fiscal Year: 2003
    ..inbred mouse strains and in mouse models of bone marrow failure at steady-state and after challenge with agents (mitomycin C and chloramphenicol) that can induce bone marrow failure...
  50. MITOMYCIN C-DNA ADDUCTS IN TUMOR CELLS
    Maria Tomasz; Fiscal Year: 1999
    ..goal of the proposed studies is to elucidate critical cellular mechanisms involved int he antitumor activity of mitomycin C (MC), a natural product widely employed in clinical cancer chemotherapy, and to translate this information ..
  51. A Proposal for the Synthesis of the Lomaiviticin Aglycon
    CARLOS ARIEL GUERRERO; Fiscal Year: 2010
    ..cell lines and exhibited a cytotoxicity profile that differed from the known DNA-damaging drugs adriamycin and mitomycin C suggesting an unprecedented mechanism of action...
  52. CELLULAR GENETIC ASPECTS OF OPIATE USE
    Arthur Falek; Fiscal Year: 1993
    ..by unscheduled DNA synthesis and an alteration in sister chromatid exchange response when stressed by UV and mitomycin C...
  53. QUINONE REDUCTASE REGULATION & QUINONE ANTICANCER DRUGS
    Su Shu Pan; Fiscal Year: 1999
    ..application are to ascertain 1) the mechanism of NQO1 regulation in human colon cancer HCT 116 cells and its mitomycin C (MMC)-resistant sublines and 2) ways to induce NQO1 in human tumor cells that augment the cytotoxicity of ..
  54. MODULATION OF ANTITUMOR DRUG ACTION BY DNA REPAIR
    Raymond Meyn; Fiscal Year: 1990
    ..g., nitrogen mustard, melphalan, and 1,3-bis(2-chloroethyl)-1-nitrosourea; cis-diamminedichloroplatinum; and mitomycin-C. The proposed work is divided into 3 specific aims...
  55. PHARMACOLOGY-BASED EFFICACY TRIAL OF INTRAVESICAL MMC
    JESSIE AU; Fiscal Year: 2000
    This is one of the three interactive applications. Our previous pharmacologic studies of intravesical mitomycin C (MMC) therapy for patients with superficial bladder cancer suggest several treatment parameters which can be optimized to ..
  56. ENHANCED PREFERENTIAL CYTOTOXICITY BY RADICAL SCAVENGERS
    Chris Pritsos; Fiscal Year: 1992
    ..Agents such as Adriamycin and mitomycin c have been shown to be preferentially cytotoxic to the more difficultly eradicated hypoxic tumor cells versus ..
  57. Combinatorial Biosynthesis of Novel Bioreductive Agents
    Yingqing Mao; Fiscal Year: 2002
    The structural and biosynthetic similaritybetween FR900482 and mitomycin (MC) group of antitumor antibiotics makes it promising to rationally create novel mitomycin/FR900482 hybrids through combinatorial biosynthesis...
  58. OXYGEN RADICALS AND ANTICANCER QUINONES
    James Doroshow; Fiscal Year: 1980
    The quinone-containing anticancer agents, including the anthracyclines and mitomycin C play an important role in the treatment of a wide variety of human malignancies...
  59. PRAJA-1: A NOVEL ANTI-APOPTOSIS RING FINGER PROTEIN
    Lopa Mishra; Fiscal Year: 2003
    ..apoptotic stimuli produced by different xenobiotic agents such as calphostin C, methotrexate etoposide and mitomycin. C reduce the expression of praja-1 (ii) whether ectopic over-expression of praja-1 renders 32Dcl3 cells less ..
  60. Phase II randomized trial of CPT-11 and Mitomycin C
    MIGUEL VILLALONA; Fiscal Year: 2003
    ..upregulation of topoisomerase I (Topo I) activity, the target enzyme for CPT-11, after administration of mitomycin C (MMC) and our observation that CPT-11 decreases the levels of DT-Diaphorase (NQ0R), we recently completed a ..
  61. Evaluation of DNA Cross-Linking by Aziridinomitosenes
    Don Warner; Fiscal Year: 2009
    Aziridinomitosenes (AZMs) are related to the clinically useful anti-cancer agent mitomycin C (MC)...
  62. HEMATOPOIESIS AND LEUKEMIC TRANSFORMATION IN FAC MICE
    DAVID CLAPP; Fiscal Year: 2003
    ..that hematopoietic progenitors from mice that are homozygous for a disruption of FancC are hypersensitive to mitomycin c in myeloid progenitor assays similar to the mitomycin c hypersensitivity observed in progenitors cultured from ..